A Philadelphia-based biotech startup — by way of Rutgers University in New Jersey — has raised an early round of cash to fund the development of RNA-based drugs that leverage a novel scientific discovery to shut down disease-causing genes.
Ceptur Therapeutics launched Wednesday with a $75 million Series A round of financing collected from venture capital firms, health care hedge funds, and Bristol Myers Squibb.
The young company’s technology is based on novel discoveries made by Sam Gunderson, a professor of molecular biology at Rutgers University, into a molecule called a U1 Adaptor that works inside the nucleus to control gene expression and stops the maturation of messenger RNA.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
